Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Añadir filtros








Intervalo de año
1.
Drug Evaluation Research ; (6): 1157-1162, 2017.
Artículo en Chino | WPRIM | ID: wpr-660914

RESUMEN

Objective o evaluate the efficacy and safety of perampanel in the treatment of refractory partial-onset seizures.Methods The randomized controlled trials ofperampanel in treatment of refractory partial-onset seizures were searched from PubMed,EBSCO,EMbase,Cochrane Library,CBM,CNKI,VIP database,and Wanfang database by computer.Data were collected from establishment of the database to February 2017 and the each index was analyzed by meta-analysis with RevMan 5.0 software.Results Five RCT were included,including 1 500 patients with refractory partial-onset seizures.Meta-analysis results showed that there was a significant difference between perampanel and placebo in term of seizure-free rate [OR=3.75,95%CI(1.77,7.93),P =0.000 6] and percentage of patients achieving 50% reduction in seizure frequency [OR=2.08,95%CI(1.69,2.56),P < 0.001].Common adverse reactions of perampanel were dizziness,somnolence,headache,ataxia,nasopharyngifis,etc.The total rate of adverse reactions of the two Perampanel groups of 8 mg group and 12 mg group doses were higher than placebo group (P < 0.05).Conclusion The clinical efficacy of perampanel in the treatment of refractory partial-onset seizures,and the adverse reactions is slight,patient is well tolerated.

2.
Drug Evaluation Research ; (6): 1157-1162, 2017.
Artículo en Chino | WPRIM | ID: wpr-662869

RESUMEN

Objective o evaluate the efficacy and safety of perampanel in the treatment of refractory partial-onset seizures.Methods The randomized controlled trials ofperampanel in treatment of refractory partial-onset seizures were searched from PubMed,EBSCO,EMbase,Cochrane Library,CBM,CNKI,VIP database,and Wanfang database by computer.Data were collected from establishment of the database to February 2017 and the each index was analyzed by meta-analysis with RevMan 5.0 software.Results Five RCT were included,including 1 500 patients with refractory partial-onset seizures.Meta-analysis results showed that there was a significant difference between perampanel and placebo in term of seizure-free rate [OR=3.75,95%CI(1.77,7.93),P =0.000 6] and percentage of patients achieving 50% reduction in seizure frequency [OR=2.08,95%CI(1.69,2.56),P < 0.001].Common adverse reactions of perampanel were dizziness,somnolence,headache,ataxia,nasopharyngifis,etc.The total rate of adverse reactions of the two Perampanel groups of 8 mg group and 12 mg group doses were higher than placebo group (P < 0.05).Conclusion The clinical efficacy of perampanel in the treatment of refractory partial-onset seizures,and the adverse reactions is slight,patient is well tolerated.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA